NIH Weekly Funding Opportunities and Policy Notices
Understanding Suicide Risk and Protective Factors among Black Youth (R21 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-22-141 from the NIH Guide for Grants and Contracts. Proposed as a priority under the Suicide Prevention Transformational Project Strategic Plan, this funding opportunity is aligned with NIMHs commitment to support research that builds on existing efforts to understand and prevent youth suicide, especially for groups at elevated risk. This funding opportunity aims to better identify and understand risk factors that contribute to recent increases in suicide among Black Youth as well as protective factors that may be targeted for future interventions.
Understanding Suicide Risk and Protective Factors among Black Youth (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-22-140 from the NIH Guide for Grants and Contracts. Proposed as a priority under the Suicide Prevention Transformational Project Strategic Plan, this funding opportunity is aligned with NIMHs commitment to support research that builds on existing efforts to understand and prevent youth suicide, especially for groups at elevated risk. This funding opportunity aims to better identify and understand risk factors that contribute to recent increases in suicide among Black Youth as well as protective factors that may be targeted for future interventions.
BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-22-220 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-21-135. This FOA supports the development of software to visualize and analyze the data as part of programs of building the informatics infrastructure for the BRAIN Initiative. Other informatics programs include developing data standards that are needed to describe the new experiments that are being created by or used in the BRAIN Initiative ( RFA-MH-19-146 ), and creating the data infrastructures that will house the data from multiple experimental groups ( RFA-MH-19-145 ). Each of the programs is aimed at building an infrastructure that is used by a particular sub-domain of experimentalists rather than building a single all-encompassing informatics infrastructure now. Building the infrastructure one experimental area at a time will ensure that the infrastructure is immediately useful to components of the research community. As our understanding of the brain improves, it may be possible to create linkages between these various sub-domain specific informatics programs. Investigators of the informatics programs should keep that goal in mind and build for the future even though the current efforts are more limited in scope.
Funding Opportunity RFA-MD-22-008 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to (1) understand the underlying mechanisms and (2) test interventions to address and mitigate the impact of health-related misinformation and disinformation on health disparities and the populations that experience health disparities.?
Notice NOT-AT-22-017 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-126 from the NIH Guide for Grants and Contracts. This initiative will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high risk approaches with potential for significant impact. Projects should entail a high degree of risk or novelty, which will be offset by a correspondingly high potential impact. However, the possible impact is likely to be far off. Application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. The goal of this FOA is to support proof of concept studies for feasibility and exploratory technology development. Feasibility must not have already been established in the literature or with preliminary data. Published data can be used to establish the current state of the art but cannot forecast or predict project outcomes. Preliminary data for any purpose might appear to forecast the likelihood of success. Therefore, no unpublished data is allowed. While unpublished data are not permitted, references and data from widely available preprints that have a Digital Object Identifier (DOI) are acceptable.
Funding Opportunity PAR-22-127 from the NIH Guide for Grants and Contracts. This initiative will support projects that focus solely on development of technologies with the potential to enable acquisition of basic biomedical knowledge. Projects should be justified in terms of technical innovation, and utility for future biomedical impact.The products of this research will be functioning prototype instruments, methods, synthetic approaches, biological products, etc., characterized adequately to be ready for first application to the type of biomedical research questions that provide the rationale for their development, but application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded.Proof of principle for the technology will have already been shown, but there will still be significant fundamental technical challenges. Applications should include preliminary data. Projects that have significant remaining risk but are supported by early feasibility studies might be appropriate for a three year R01 proposal with reduced budget to better manage risk and investment. Projects that are well supported by feasibility studies and propose to develop fully functional prototypes might require higher budgets and a four year duration (five years for early stage investigators). Projects that primarily focus on optimization, hardening, or obvious extrapolations of established technology might be less competitive.
Funding Opportunity PAR-22-076 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). Studies proposed should provide a cost-effective means of collecting data with a meaningful bearing on current clinical practice. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a observational study phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for observational studies will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of data collection, storage, and planned analyses. Operational planning activities include, at a minimum, development of recruitment and retention strategies, case report forms, data management system and other tools for data and quality management. The UH3 phase of the award will support the conduct of investigator-initiated observational study.
Notice NOT-EB-22-006 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-23-014 from the NIH Guide for Grants and Contracts. oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. In recent years, there have been significant advances in methods and technologies for the identification of novel targets, mechanisms, and pathways of interest to substance use disorders and in identification of probes and optimized compounds for developing novel therapeutic agents. This FOA is to enable investigators with knowledge in the emerging chemical, pharmacological, and drug discovery technologies to pursue innovative and transformative research on chemical and pharmacological aspects of substance use disorders.
Notice NOT-ES-22-008 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-086 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-017 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR and STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early-stage technology development. This FOA seeks to address both challenges simultaneously by having two equally important goals; entrepreneurial mentoring support, and product development support.
Notice NOT-TR-22-025 from the NIH Guide for Grants and Contracts
Notice NOT-TR-22-026 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-075 from the NIH Guide for Grants and Contracts
Notice NOT-RM-22-011 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-139 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.
Funding Opportunity PAR-22-140 from the NIH Guide for Grants and Contracts. The STRIPE program seeks to support pre-clinical research projects utilizing state-of-the-art cancer biology methods and model systems that study how radiopharmaceutical therapy (RPT) agents affect the biology of normal tissue, tumor cells and the tumor microenvironment. Ideally, proposed aims will be designed to test hypotheses on how RPT dynamically impacts cancer biology processes, which can serve as the pre-clinical basis for developing new targeting strategies and approaches. Studies supported by this PAR will ultimately inform the rationale and design of new RPT-based clinical trials.
Notice NOT-AT-22-016 from the NIH Guide for Grants and Contracts